Sonoma Pharmaceuticals, Inc. Announces Amendment to Distribution Agreement

Expanding Access to Innovative Healthcare Products

Clever, personable, and wonderfully unconventional, Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) is a global healthcare leader that is making waves in the industry with its patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products. These products are revolutionizing healthcare by providing solutions for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care.

Distribution Agreement in Canada:

Sonoma Pharmaceuticals, Inc. has recently announced that it has entered into an amendment to its distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in Canada. This strategic move will allow Sonoma to further expand its reach and make its innovative products more accessible to healthcare providers and patients in Canada.

Previously, Sonoma had entered into a distribution agreement with a global healthcare distributor for the marketing and distribution of its wound care products in the United States. These products were to be sold through hospital systems and other healthcare channels, demonstrating Sonoma’s commitment to bringing cutting-edge solutions to the healthcare market.

Impact on Individuals

For individuals in Canada, this amendment to the distribution agreement will mean increased access to Sonoma’s innovative wound care products. Patients can benefit from the advanced technology and effectiveness of Microcyn® technology based stabilized hypochlorous acid (HOCl) products, improving their wound care outcomes and overall quality of life.

Global Impact

This announcement by Sonoma Pharmaceuticals, Inc. marks a significant step towards expanding access to advanced healthcare products on a global scale. By partnering with leading global healthcare distributors, Sonoma is positioning itself as a key player in the healthcare industry, with the potential to make a positive impact on healthcare systems worldwide.

Conclusion

Sonoma Pharmaceuticals, Inc.’s amendment to its distribution agreement is a testament to the company’s commitment to innovation and excellence in healthcare. By expanding access to its revolutionary products, Sonoma is paving the way for a brighter future in healthcare, both at an individual and global level.